Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126194851 | 12619485 | 1 | I | 201607 | 20160801 | 20160803 | 20160803 | PER | US-PFIZER INC-2016370440 | PFIZER | 49.00 | YR | F | Y | 112.40000 | KG | 20160803 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126194851 | 12619485 | 1 | PS | PRISTIQ EXTENDED-RELEASE | DESVENLAFAXINE SUCCINATE | 1 | 50 MG, 1X/DAY | U | 21992 | 50 | MG | PROLONGED-RELEASE TABLET | QD | ||||||
| 126194851 | 12619485 | 2 | I | PRISTIQ EXTENDED-RELEASE | DESVENLAFAXINE SUCCINATE | 1 | 100MG DAILY | U | 21992 | 100 | MG | PROLONGED-RELEASE TABLET | |||||||
| 126194851 | 12619485 | 3 | I | PRISTIQ EXTENDED-RELEASE | DESVENLAFAXINE SUCCINATE | 1 | 50MG DAILY | U | 21992 | 50 | MG | PROLONGED-RELEASE TABLET | |||||||
| 126194851 | 12619485 | 4 | I | VENLAFAXINE HCL | VENLAFAXINE HYDROCHLORIDE | 1 | Oral | 150 MG, 2X/DAY | U | MR11482 | 0 | 150 | MG | CAPSULE | BID | ||||
| 126194851 | 12619485 | 5 | I | VENLAFAXINE HCL | VENLAFAXINE HYDROCHLORIDE | 1 | 150MG ONCE THAT DAY | U | MR11482 | 0 | 150 | MG | CAPSULE | QD | |||||
| 126194851 | 12619485 | 6 | I | VENLAFAXINE HCL | VENLAFAXINE HYDROCHLORIDE | 1 | Oral | 75MG ONCE A DAY | U | MR11482 | 0 | 75 | MG | CAPSULE | QD | ||||
| 126194851 | 12619485 | 7 | I | VENLAFAXINE HCL | VENLAFAXINE HYDROCHLORIDE | 1 | Oral | 150 MG, 1X/DAY | U | MR11482 | 0 | 150 | MG | CAPSULE | QD | ||||
| 126194851 | 12619485 | 8 | C | ALEVE | NAPROXEN SODIUM | 1 | 440 MG, 2X/DAY | 0 | 440 | MG | BID | ||||||||
| 126194851 | 12619485 | 9 | C | ZYRTEC | CETIRIZINE HYDROCHLORIDE | 1 | 10MG EVERY DAY | 0 | 10 | MG |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126194851 | 12619485 | 1 | Depression |
| 126194851 | 12619485 | 2 | Anxiety |
| 126194851 | 12619485 | 4 | Depression |
| 126194851 | 12619485 | 5 | Anxiety |
| 126194851 | 12619485 | 8 | Osteoarthritis |
| 126194851 | 12619485 | 9 | Hypersensitivity |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126194851 | 12619485 | Activities of daily living impaired | |
| 126194851 | 12619485 | Bradyphrenia | |
| 126194851 | 12619485 | Drug dose omission | |
| 126194851 | 12619485 | Drug ineffective | |
| 126194851 | 12619485 | Drug interaction | |
| 126194851 | 12619485 | Fatigue | |
| 126194851 | 12619485 | Headache | |
| 126194851 | 12619485 | Hot flush | |
| 126194851 | 12619485 | Intentional product misuse | |
| 126194851 | 12619485 | Therapeutic response unexpected | |
| 126194851 | 12619485 | Visual brightness |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126194851 | 12619485 | 1 | 20160720 | 20160723 | 0 | |
| 126194851 | 12619485 | 2 | 20160724 | 20160727 | 0 | |
| 126194851 | 12619485 | 3 | 20160728 | 20160728 | 0 | |
| 126194851 | 12619485 | 4 | 1991 | 201607 | 0 | |
| 126194851 | 12619485 | 5 | 20160723 | 20160723 | 0 | |
| 126194851 | 12619485 | 6 | 20160724 | 20160728 | 0 | |
| 126194851 | 12619485 | 7 | 20160729 | 0 | ||
| 126194851 | 12619485 | 8 | 2016 | 0 | ||
| 126194851 | 12619485 | 9 | 2011 | 0 |